Substantial doubt about ability to continue as a going concern
Company stated it lacks sufficient cash to fund 12 months of operations without additional financing.
- Scope
- Liquidity and capital markets access
- Materiality
- high
AEON Biopharma, Inc.
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing prabotulinumtoxinA injection (ABP-450) for therapeutic (non-cosmetic) uses as a proposed BOTOX biosimilar in the United States. The company’s strategy is to pursue a Section 351(k) biosimilar Biologics License Application (BLA), using AbbVie’s Botox as the reference product, targeting debilitating medical conditions. ABP-450 is manufactured by Daewoong Pharmaceutical in a cGMP facility that has been approved by the FDA, Health Canada, and the EMA, and the same toxin complex is already approved as a biosimilar in certain international markets. AEON holds exclusive development and distribution rights for certain therapeutic uses across the U.S., Canada, the EU, the UK, and select other territories, positioning it to commercialize if it achieves regulatory approval.
0.49
0.49
| % | |
|---|---|
| ABP-450 therapeutic biosimilar development | 85% R&D and regulatory work to develop ABP-450 as a therapeutic botulinum toxin biosimilar via a 351(k) BLA. |
| Analytical/clinical comparability and trials | 10% Structural analysis and clinical studies (e.g., comparability in cervical dystonia) to support biosimilarity and indications. |
| Commercial readiness and market access preparation | 5% Pre-launch planning activities needed to commercialize ABP-450 if approved, including distribution readiness. |
AEON does not currently generate product revenue and is not yet commercializing ABP-450; its end-market customers would...
- Specialist physicians and clinics (therapeutic use)primary
Would use ABP-450 for approved therapeutic indications where botulinum toxin injections are part of care pathways.
- Hospitals and integrated delivery networkssecondary
Would procure product through formulary processes and buy-and-bill workflows for outpatient and specialty clinics.
- Payors and pharmacy/medical benefit managersprimary
Would determine coverage and reimbursement, influencing provider adoption and patient access for biosimilar therapy.
- Specialty distributors and channel partnerssecondary
Would handle storage, logistics, and distribution to provider sites for an injectable biologic product.
AEON is U.S.-based and is primarily focused on achieving U.S. market entry for ABP-450 through a 351(k) BLA pathway...
- •Primary near-term focus is U.S. FDA approval and launch planning
- •Rights extend to Canada, EU, UK for certain therapeutic uses
- •Manufacturing is outsourced to Daewoong (cGMP; FDA/EMA/HC approved)
- •International prior approvals (e.g., Mexico, India, Philippines) inform risk
- •Cross-border supply chain increases quality and logistics complexity
AEON’s core strategy is to develop ABP-450 as a therapeutic BOTOX biosimilar and pursue U.S...
01
Generate biosimilarity package for a 351(k) BLAshort-term
Approval requires robust analytical and clinical evidence against the reference product.
02
Expand therapeutic indication set for ABP-450medium-term
More indications can increase addressable market and strengthen commercial rationale.
03
Fundraising to extend operating runwayshort-term
The company disclosed substantial doubt about going concern without additional financing.
AEON is pre-revenue and depends on successful clinical development and regulatory approval of ABP-450; delays or...
No revenue until regulatory approval and commercialization
Company disclosed it has never generated revenue from ABP-450 and does not expect revenue until approval.
- Scope
- Business model depends on a single late-stage inflection
- Materiality
- high
Reliance on third-party manufacturer (Daewoong) for ABP-450 supply
ABP-450 is manufactured externally; any disruption or compliance issue could delay trials or launch.
- Scope
- Supply chain and quality systems
- Materiality
- medium
Fair value measurement of contingent consideration
High volatility in other income/expense and net results
Accounting for warrants, convertible notes, and derivative liabilities
Quarterly comparability and valuation-sensitive P&L items
Stock-based compensation
Higher reported operating expenses vs. cash operating costs
ABEONA THERAPEUTICS INC.
ABEO · Pharmaceutical Preparations
ProtoKinetix, Inc.
PKTX · Pharmaceutical Preparations
Xenon Pharmaceuticals Inc.
XENE · Pharmaceutical Preparations
AIBOTICS, INC.
AIBT · Medicinal Chemicals & Botanical Products
BeOne Medicines Ltd.
ONC · Pharmaceutical Preparations
AETHLON MEDICAL INC
AEMD · Surgical & Medical Instruments & Apparatus
: 11/08/2026